Elicera Therapeutics AB operates as a clinical stage immuno-oncology company, which engages in the development of cell and gene therapies for immune-based cancer treatments. Its drug candidates are in the field of oncolytic viruses and in the field of cell therapies, in addition to a platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune enhancement of treatments in said fields. Its product pipeline includes ELC-100, ELC-201, ELC-301, and ELC-401. The company was founded by Jamal El-Mosleh, Di Yu, and Magnus Essand in 2014 and is headquartered in Gothenburg, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company